Provided by Tiger Fintech (Singapore) Pte. Ltd.

Equillium Inc.

0.7200
+0.01001.41%
Volume:43.17K
Turnover:31.11K
Market Cap:25.51M
PE:-5.50
High:0.7450
Open:0.6930
Low:0.6900
Close:0.7100
Loading ...

Company Profile

Company Name:
Equillium Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
45
Office Location:
2223 Avenida De La Playa,Suite 105,La Jolla,California,United States
Zip Code:
92037
Fax:
- -
Introduction:
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Directors

Name
Position
Bruce D. Steel
Director,President and Chief Executive Officer
Daniel M. Bradbury
Director, Executive Chairman
Stephen Connelly
Director,Chief Scientific Officer
Bala S. Manian
Director
Charles McDermott
Director
Mark Pruzanski
Director
Martha J. Demski
Director

Shareholders

Name
Position
Bruce D. Steel
Director,President and Chief Executive Officer
Christine Zedelmayer
Senior Vice President, Chief Operating Officer
Jason A. Keyes
Chief Financial Officer
Krishna R. Polu
Executive Vice President, Research and Development
Stephen Connelly
Director,Chief Scientific Officer